COMPANY

CereMark Pharma

HQ: Wheeling, WV source · ceremarkpharma.com ↗

CereMark Pharma is listed on ClinicalTrials.gov as the lead sponsor of 1 study; the most recently updated is “Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease” (Phase 3, recruiting), in Alzheimer Disease, Chronic Traumatic Encephalopathy. From public records Source · Oct 12, 2026

Keywords: Alzheimer Alzheimer Disease

Location: Wheeling, WV · source · Oct 15, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Timeline

Jul 1, 2025 Trial start Phase 3: Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy o source ↗

Upcoming milestones

Jun 30, 2028 (ESTIMATED) · Phase 3 · Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheim · NCT06254469

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT06254469	Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease	Phase 3	Recruiting	Jul 1, 2025	Jun 30, 2028 (estimated)